ImmunoGen, Inc. (NASDAQ:IMGN) has been given an average rating of “Hold” by the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $7.30.
Several research firms recently issued reports on IMGN. Cantor Fitzgerald reiterated a “hold” rating and set a $5.00 target price on shares of ImmunoGen in a report on Friday, November 3rd. Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research note on Tuesday, October 31st. Jefferies Group restated a “buy” rating and issued a $9.00 price objective on shares of ImmunoGen in a research note on Thursday, October 12th. Finally, ValuEngine lowered ImmunoGen from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st.
ImmunoGen (IMGN) traded up $0.23 on Wednesday, reaching $7.79. The company had a trading volume of 2,462,100 shares, compared to its average volume of 2,404,381. ImmunoGen has a fifty-two week low of $2.20 and a fifty-two week high of $8.84. The company has a market capitalization of $999.81, a price-to-earnings ratio of -5.99 and a beta of 2.20. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03.
ImmunoGen (NASDAQ:IMGN) last released its earnings results on Friday, November 3rd. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.42). The company had revenue of $8.50 million during the quarter, compared to analyst estimates of $26.09 million. During the same quarter in the previous year, the firm earned ($0.51) EPS. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. equities research analysts anticipate that ImmunoGen will post -0.97 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in IMGN. Arrowstreet Capital Limited Partnership bought a new stake in ImmunoGen in the second quarter valued at approximately $102,000. Intl Fcstone Inc. bought a new stake in ImmunoGen in the second quarter valued at approximately $115,000. Raymond James Financial Services Advisors Inc. bought a new stake in ImmunoGen in the second quarter valued at approximately $126,000. Virginia Retirement Systems ET AL bought a new stake in ImmunoGen in the third quarter valued at approximately $136,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of ImmunoGen during the third quarter worth approximately $143,000. Hedge funds and other institutional investors own 68.02% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/14/brokerages-set-immunogen-inc-imgn-target-price-at-7-30.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.